<?xml version='1.0' encoding='utf-8'?>
<document id="30891820"><sentence text="Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone."><entity charOffset="24-41" id="DDI-PubMed.30891820.s1.e0" text="prostaglandin F2α" /><entity charOffset="104-121" id="DDI-PubMed.30891820.s1.e1" text="magnesium sulfate" /><entity charOffset="123-131" id="DDI-PubMed.30891820.s1.e2" text="atosiban" /><entity charOffset="133-143" id="DDI-PubMed.30891820.s1.e3" text="nifedipine" /><entity charOffset="148-161" id="DDI-PubMed.30891820.s1.e4" text="betamethasone" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e0" e2="DDI-PubMed.30891820.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e0" e2="DDI-PubMed.30891820.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e0" e2="DDI-PubMed.30891820.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e0" e2="DDI-PubMed.30891820.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e0" e2="DDI-PubMed.30891820.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e1" e2="DDI-PubMed.30891820.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e1" e2="DDI-PubMed.30891820.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e1" e2="DDI-PubMed.30891820.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e1" e2="DDI-PubMed.30891820.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e2" e2="DDI-PubMed.30891820.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e2" e2="DDI-PubMed.30891820.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e2" e2="DDI-PubMed.30891820.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e3" e2="DDI-PubMed.30891820.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30891820.s1.e3" e2="DDI-PubMed.30891820.s1.e4" /></sentence><sentence text="To investigate presence or absence of clinically relevant drug interactions (pharmacokinetic and safety/tolerability) of OBE022 with standard-of-care medicines for preterm labour, enabling coadministration and further clinical development" /><sentence text="" /><sentence text="Part A: open-label, randomized, 3-period crossover assessing coadministration of single doses of OBE022 (1100 mg) and MgSO4 "><entity charOffset="97-103" id="DDI-PubMed.30891820.s4.e0" text="OBE022" /><entity charOffset="118-123" id="DDI-PubMed.30891820.s4.e1" text="MgSO4" /><pair ddi="false" e1="DDI-PubMed.30891820.s4.e0" e2="DDI-PubMed.30891820.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30891820.s4.e0" e2="DDI-PubMed.30891820.s4.e1" /></sentence><sentence text=" Part B: open-label, single-sequence crossover assessing the interactions following administration of OBE022 (1000 mg/day) at steady state coadministered with single doses of atosiban, nifedipine and betamethasone"><entity charOffset="185-195" id="DDI-PubMed.30891820.s5.e0" text="nifedipine" /><entity charOffset="200-213" id="DDI-PubMed.30891820.s5.e1" text="betamethasone" /><pair ddi="false" e1="DDI-PubMed.30891820.s5.e0" e2="DDI-PubMed.30891820.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30891820.s5.e0" e2="DDI-PubMed.30891820.s5.e1" /></sentence><sentence text=" Twenty-five healthy nonpregnant women of reproductive age were enrolled (Part A: n = 12; Part B: n = 13)" /><sentence text="" /><sentence text="OBE022, alone or in combination with standard-of-care medications, was well tolerated" /><sentence text=" Headache and dizziness were the most frequently reported adverse events; dizziness occurred more often with the nifedipine/OBE022 combination"><entity charOffset="113-123" id="DDI-PubMed.30891820.s9.e0" text="nifedipine" /></sentence><sentence text=" There were no clinically significant pharmacokinetic interactions when coadministered with MgSO4 "><entity charOffset="92-97" id="DDI-PubMed.30891820.s10.e0" text="MgSO4" /></sentence><sentence text=" Co-administration had no notable effect on atosiban exposure" /><sentence text=" Atosiban reduced exposure to OBE002 (peak concentration [Cmax ] 22%, area under the concentration-time curve [AUC] 19%)" /><sentence text=" Coadministration with betamethasone slightly increased betamethasone exposure (Cmax  + 18%, AUC +27%) and OBE002 exposure (Cmax  + 35%, AUC +15%)"><entity charOffset="23-36" id="DDI-PubMed.30891820.s13.e0" text="betamethasone" /><entity charOffset="56-69" id="DDI-PubMed.30891820.s13.e1" text="betamethasone" /><pair ddi="false" e1="DDI-PubMed.30891820.s13.e0" e2="DDI-PubMed.30891820.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30891820.s13.e0" e2="DDI-PubMed.30891820.s13.e1" /></sentence><sentence text=" These changes were not considered clinically significant" /><sentence text=" Coadministration with nifedipine slightly increased OBE002 exposure (Cmax  + 29%, AUC +24%) and markedly increased nifedipine exposure (Cmax by 2-fold and AUC by 2-fold), which may be clinically significant"><entity charOffset="23-33" id="DDI-PubMed.30891820.s15.e0" text="nifedipine" /><entity charOffset="116-126" id="DDI-PubMed.30891820.s15.e1" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.30891820.s15.e0" e2="DDI-PubMed.30891820.s15.e0" /><pair ddi="false" e1="DDI-PubMed.30891820.s15.e0" e2="DDI-PubMed.30891820.s15.e1" /></sentence><sentence text="" /><sentence text="The use of OBE022, a PGF2α antagonist prodrug, in combination with standard-of-care medicines may provide new treatment alternatives for preterm labour"><entity charOffset="11-17" id="DDI-PubMed.30891820.s17.e0" text="OBE022" /></sentence><sentence text=" All tested combinations were well tolerated" /><sentence text=" Nifedipine doses could potentially be reduced or staggered when coadministered with OBE022"><entity charOffset="1-11" id="DDI-PubMed.30891820.s19.e0" text="Nifedipine" /></sentence><sentence text="" /></document>